Alzheimer’s disease MCQs With Answer provides B. Pharm students a concise, exam-focused review of Alzheimer’s disease pathophysiology, pharmacology, diagnosis, and therapeutics. This Student-friendly post covers key concepts such as amyloid-beta plaques, tau pathology, cholinergic deficits, biomarkers (CSF Aβ42, tau), cognitive assessment (MMSE), and primary drug classes including cholinesterase inhibitors, NMDA antagonists, and anti-amyloid monoclonal antibodies. The resource emphasizes clinical pharmacology, drug mechanisms, adverse effects, pharmacokinetics, and drug interactions relevant to pharmacy practice. Ideal for revision, it builds deeper understanding needed for exams and clinical dispensing. Now let’s test your knowledge with 50 MCQs on this topic.
Q1. What are the two classic neuropathological hallmarks of Alzheimer’s disease?
- Lewy bodies and neurofibrillary tangles
- Ischemic infarcts and amyloid angiopathy
- Amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau
- Synaptic pruning and demyelination
Correct Answer: Amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau
Q2. Which neurotransmitter system is primarily implicated in the cognitive symptoms of Alzheimer’s disease?
- Dopaminergic system
- Cholinergic system
- GABAergic system
- Serotonergic system
Correct Answer: Cholinergic system
Q3. Which gene allele is most strongly associated with increased risk of late-onset sporadic Alzheimer’s disease?
- PSEN1
- APP
- APOE ε4
- MAPT
Correct Answer: APOE ε4
Q4. Which cerebrospinal fluid (CSF) biomarker pattern is characteristic of Alzheimer’s disease?
- Increased Aβ42, decreased total tau
- Decreased Aβ42, increased total tau and phosphorylated tau
- No change in Aβ42, decreased phosphorylated tau
- Increased Aβ42, increased phosphorylated tau
Correct Answer: Decreased Aβ42, increased total tau and phosphorylated tau
Q5. Which cognitive test score range is commonly considered within the normal range for the Mini-Mental State Examination (MMSE)?
- 0–9
- 10–18
- 19–23
- 24–30
Correct Answer: 24–30
Q6. Which of the following drugs is a reversible acetylcholinesterase inhibitor commonly used in Alzheimer’s disease?
- Memantine
- Rivastigmine
- Donepezil
- Levodopa
Correct Answer: Donepezil
Q7. Which drug acts primarily as an NMDA receptor antagonist in moderate-to-severe Alzheimer’s disease?
- Donepezil
- Galantamine
- Memantine
- Rivastigmine
Correct Answer: Memantine
Q8. Which cholinesterase inhibitor also inhibits butyrylcholinesterase and is available as a transdermal patch?
- Donepezil
- Rivastigmine
- Galantamine
- Memantine
Correct Answer: Rivastigmine
Q9. Galantamine has a dual mechanism. Which combination best describes its action?
- NMDA antagonism and dopamine reuptake inhibition
- Reversible AChE inhibition and positive allosteric modulation of nicotinic receptors
- Irreversible AChE inhibition and GABA agonism
- Amyloid clearance and tau phosphorylation inhibition
Correct Answer: Reversible AChE inhibition and positive allosteric modulation of nicotinic receptors
Q10. Which adverse effect is most commonly associated with oral cholinesterase inhibitors?
- Hypertension
- Gastrointestinal symptoms such as nausea and vomiting
- Hyperglycemia
- Renal failure
Correct Answer: Gastrointestinal symptoms such as nausea and vomiting
Q11. Which statement about donepezil pharmacokinetics and dosing is correct?
- Donepezil requires multiple daily dosing due to a very short half-life
- Donepezil is typically given once daily because of a long half-life
- Donepezil is administered intravenously in standard practice
- Donepezil is primarily eliminated unchanged in the urine
Correct Answer: Donepezil is typically given once daily because of a long half-life
Q12. Which of the following is a common cardiovascular adverse effect of cholinesterase inhibitors?
- QT prolongation
- Tachycardia
- Bradycardia and syncope
- Hypertensive crisis
Correct Answer: Bradycardia and syncope
Q13. Which class of drugs can worsen cognitive function when given to Alzheimer’s patients due to anticholinergic effects?
- Beta blockers
- Anticholinergic medications such as tricyclic antidepressants and some antihistamines
- ACE inhibitors
- Statins
Correct Answer: Anticholinergic medications such as tricyclic antidepressants and some antihistamines
Q14. Which genetic mutations are commonly associated with early-onset familial Alzheimer’s disease?
- Mutations in APP, PSEN1, and PSEN2
- Mutations in APOE only
- Mutations in tau gene MAPT alone
- Mutations in alpha-synuclein
Correct Answer: Mutations in APP, PSEN1, and PSEN2
Q15. Which imaging modality is most useful for detecting amyloid deposition in the brain?
- CT scan without contrast
- FDG-PET for glucose metabolism
- Amyloid PET imaging using specific tracers
- Standard MRI T1-weighted imaging
Correct Answer: Amyloid PET imaging using specific tracers
Q16. Which of the following best describes the primary therapeutic goal of current cholinesterase inhibitor treatment in Alzheimer’s disease?
- To cure Alzheimer’s disease by removing plaques
- To provide symptomatic cognitive improvement and slow functional decline modestly
- To reverse neurofibrillary tangles permanently
- To prevent cardiovascular complications of dementia
Correct Answer: To provide symptomatic cognitive improvement and slow functional decline modestly
Q17. Aducanumab and lecanemab are examples of which therapeutic approach?
- Small-molecule NMDA antagonists
- Anticholinergic agents
- Monoclonal antibodies targeting amyloid-beta
- Serotonin reuptake inhibitors
Correct Answer: Monoclonal antibodies targeting amyloid-beta
Q18. Which adverse event is a recognized risk of anti-amyloid monoclonal antibody therapy?
- Progressive multifocal leukoencephalopathy
- Amyloid-related imaging abnormalities (ARIA) including edema and microhemorrhages
- Severe hyperglycemia
- Acute myocardial infarction
Correct Answer: Amyloid-related imaging abnormalities (ARIA) including edema and microhemorrhages
Q19. What is the primary pathophysiological role attributed to amyloid-beta in Alzheimer’s disease?
- Primary neurotransmitter deficiency
- Extracellular aggregation leading to plaque formation and synaptic dysfunction
- Intracellular viral replication
- Direct demyelination of white matter tracts
Correct Answer: Extracellular aggregation leading to plaque formation and synaptic dysfunction
Q20. Which staging concept describes the progression from no symptoms to detectable pathology prior to cognitive impairment?
- Rapid-onset dementia
- Preclinical Alzheimer’s disease
- Vascular cognitive impairment
- Late-stage Alzheimer’s only
Correct Answer: Preclinical Alzheimer’s disease
Q21. Which clinical feature is more suggestive of Lewy body dementia than Alzheimer’s disease?
- Early prominent memory loss only
- Visual hallucinations and parkinsonism
- Progressive aphasia with preserved visuospatial skills
- Symmetric pure motor weakness
Correct Answer: Visual hallucinations and parkinsonism
Q22. Which enzyme metabolizes donepezil and can be involved in drug interactions?
- CYP3A4 and CYP2D6
- Monoamine oxidase
- Acetyltransferase only
- Renal dehydrogenase
Correct Answer: CYP3A4 and CYP2D6
Q23. Which statement about rivastigmine’s mechanism is correct?
- Rivastigmine is a selective muscarinic receptor antagonist
- Rivastigmine irreversibly inhibits monoamine oxidase
- Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase
- Rivastigmine is a direct NMDA receptor agonist
Correct Answer: Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase
Q24. Which formulation of rivastigmine is associated with reduced gastrointestinal adverse effects?
- Immediate-release oral capsule
- Intramuscular injection
- Transdermal patch
- Intravenous infusion
Correct Answer: Transdermal patch
Q25. Which of the following best describes the effect of memantine when combined with a cholinesterase inhibitor?
- No added benefit and high toxicity
- Often used together for additive symptomatic benefit in moderate-to-severe Alzheimer’s disease
- Antagonizes cholinesterase inhibitors’ mechanism and is contraindicated
- Completely reverses disease progression
Correct Answer: Often used together for additive symptomatic benefit in moderate-to-severe Alzheimer’s disease
Q26. Which risk factor is considered the most important for developing Alzheimer’s disease?
- Hypertension in childhood
- Older age
- High vitamin D levels
- Frequent physical activity
Correct Answer: Older age
Q27. Which neuropathological change in Alzheimer’s disease is most directly linked to disruption of neuronal microtubules?
- Amyloid-beta plaque accumulation
- Neurofibrillary tangles formed by hyperphosphorylated tau
- Alpha-synuclein inclusions
- Lewy bodies in the cortex
Correct Answer: Neurofibrillary tangles formed by hyperphosphorylated tau
Q28. Which clinical trial endpoint is commonly used to assess cognitive change in Alzheimer’s trials?
- HbA1c reduction
- Mini-Mental State Examination (MMSE) or ADAS-Cog scores
- Electrocardiogram QT interval
- Forced expiratory volume (FEV1)
Correct Answer: Mini-Mental State Examination (MMSE) or ADAS-Cog scores
Q29. Which therapeutic strategy aims to enhance clearance or reduce production of amyloid-beta?
- Cholinesterase inhibition
- Monoclonal antibodies and secretase modulators
- Nutritional supplementation only
- Deep brain stimulation
Correct Answer: Monoclonal antibodies and secretase modulators
Q30. In terms of drug metabolism, which cholinesterase inhibitor is notably metabolized by CYP2D6 and CYP3A4?
- Rivastigmine
- Donepezil
- Galantamine
- Memantine
Correct Answer: Galantamine
Q31. Which of the following is a non-pharmacological intervention recommended for Alzheimer’s patients to support cognition and function?
- High-dose anticholinergic medications
- Cognitive stimulation and structured activities
- Complete sensory deprivation
- Strict bed rest without social interaction
Correct Answer: Cognitive stimulation and structured activities
Q32. Which change in brain structure is commonly observed on MRI in Alzheimer’s disease?
- Marked cerebellar atrophy only
- Generalized cortical atrophy, especially medial temporal lobe atrophy
- Focal spinal cord lesions
- Subdural hematoma
Correct Answer: Generalized cortical atrophy, especially medial temporal lobe atrophy
Q33. Which clinical feature is characteristic of early Alzheimer’s disease?
- Prominent early motor weakness
- Insidious onset of episodic memory impairment
- Acute sudden focal neurological deficit
- Primary visual loss due to optic neuritis
Correct Answer: Insidious onset of episodic memory impairment
Q34. What is the mechanism of action of memantine at the molecular level?
- Competitive blocker of nicotinic receptors
- Noncompetitive, low-to-moderate affinity NMDA receptor antagonist
- Irreversible acetylcholinesterase inhibitor
- Monoamine oxidase inhibitor
Correct Answer: Noncompetitive, low-to-moderate affinity NMDA receptor antagonist
Q35. Which medication requires slow titration to minimize adverse effects and reach a maintenance dose of 10 mg twice daily?
- Donepezil
- Memantine
- Rivastigmine patch
- Galantamine oral immediate-release reaching 8–24 mg/day
Correct Answer: Memantine
Q36. Which laboratory finding would you expect in a patient with Alzheimer’s confirmed by CSF biomarkers?
- Increased CSF Aβ42 and decreased tau
- Decreased CSF Aβ42 and increased phosphorylated tau
- Normal CSF biomarkers always
- Decreased CSF glucose only
Correct Answer: Decreased CSF Aβ42 and increased phosphorylated tau
Q37. Which of the following drugs is least likely to be helpful for cognitive symptoms of Alzheimer’s disease?
- Donepezil
- Rivastigmine
- Galantamine
- Haloperidol
Correct Answer: Haloperidol
Q38. Which factor should pharmacists counsel about when dispensing cholinesterase inhibitors to elderly patients?
- Expect immediate cure within days
- Monitor for gastrointestinal side effects, bradycardia, and drug interactions
- No need for dose adjustments in severe renal impairment for all agents
- They always cause severe hypertension
Correct Answer: Monitor for gastrointestinal side effects, bradycardia, and drug interactions
Q39. Which pathological process is directly targeted by BACE (beta-secretase) inhibitors under investigation?
- Tau hyperphosphorylation
- Production of amyloid-beta from APP
- Synthesis of acetylcholine
- Glutamate uptake by astrocytes
Correct Answer: Production of amyloid-beta from APP
Q40. Which comorbidity can mimic or worsen cognitive impairment and should be evaluated in suspected dementia?
- Hypothyroidism
- Acute appendicitis
- Chronic otitis externa only
- Peripheral artery disease without brain involvement
Correct Answer: Hypothyroidism
Q41. What is the effect of APOE ε4 on Alzheimer’s disease?
- APOE ε4 decreases risk and delays onset
- APOE ε4 increases risk and lowers the age of onset
- APOE ε4 is protective against amyloid deposition
- APOE ε4 only affects Parkinson’s disease
Correct Answer: APOE ε4 increases risk and lowers the age of onset
Q42. Which measure is most appropriate to assess functional ability in Alzheimer’s patients?
- Blood pressure measurement
- Activities of daily living (ADL) assessment
- Urinalysis
- Liver enzyme panel
Correct Answer: Activities of daily living (ADL) assessment
Q43. Which statement is true regarding the symptomatic benefits of cholinesterase inhibitors?
- They typically reverse dementia permanently
- They can provide modest cognitive and functional improvement in mild-to-moderate stages
- They are effective only for severe, late-stage disease
- They increase amyloid plaque burden
Correct Answer: They can provide modest cognitive and functional improvement in mild-to-moderate stages
Q44. Which adverse event should be monitored specially when combining cholinesterase inhibitors with beta-blockers?
- Increased risk of bradycardia and syncope
- Severe hypernatremia
- Acute liver failure
- Ototoxicity
Correct Answer: Increased risk of bradycardia and syncope
Q45. Which clinical trial result would suggest a disease-modifying effect in Alzheimer’s therapy?
- Short-term symptomatic improvement only
- Slower cognitive decline over years and biomarker changes indicating reduced pathology
- Increased adverse events with no clinical benefit
- Transient mood improvement unrelated to cognition
Correct Answer: Slower cognitive decline over years and biomarker changes indicating reduced pathology
Q46. Which diagnostic criteria set is commonly used for research and clinical classification of Alzheimer’s disease?
- DSM-III only
- NIA-AA (National Institute on Aging–Alzheimer’s Association) criteria
- WHO criteria for infectious disease
- Rome IV criteria
Correct Answer: NIA-AA (National Institute on Aging–Alzheimer’s Association) criteria
Q47. Which symptom is considered an early behavioral or neuropsychiatric manifestation of Alzheimer’s disease?
- New-onset disinhibition, apathy, or mild agitation
- Sudden full recovery of memory
- Isolated acute hemiparesis
- Chronic peripheral neuropathy pain
Correct Answer: New-onset disinhibition, apathy, or mild agitation
Q48. Which of the following best describes the clinical utility of routine amyloid PET scanning in all dementia patients?
- Recommended for all patients irrespective of symptoms
- Useful selectively when diagnosis is uncertain and impacts management
- Not useful under any circumstances
- Replaces the need for clinical assessment entirely
Correct Answer: Useful selectively when diagnosis is uncertain and impacts management
Q49. Which change in prescribing should be considered for an Alzheimer’s patient with severe renal impairment?
- No drug adjustments are ever needed for dementia drugs
- Consider dose adjustments or avoidance of agents renally cleared, such as memantine, based on renal function
- Increase doses to overcome renal dysfunction
- Switch to high-dose anticholinergics
Correct Answer: Consider dose adjustments or avoidance of agents renally cleared, such as memantine, based on renal function
Q50. Which preventive strategy has the strongest evidence to potentially reduce dementia risk later in life?
- Maintaining cardiovascular health and regular physical activity
- High-dose long-term anticholinergic use
- Smoking and sedentary lifestyle
- Ignoring vascular risk factors
Correct Answer: Maintaining cardiovascular health and regular physical activity
